Symptomatic treatment of vestibular deficits: Therapeutic potential of histamine H4 receptors
Issue title: ARO 2012 Symposium on Vestibular Neuropharmacology, New Insights on Vestibular Neuropharmacology: From Bench to Bedside - San Diego, CA, USA, February 28, 2012
Affiliations: [a] SENSORION, Montpellier, France | [b] INSERM U1051, Institute for Neurosciences Montpellier, Montpellier, France | [c] Institute of Physiology, Autonomous University of Puebla, Puebla, México | INSERM U1051 Montpellier and UMR 7260 CNRS Aix-Marseille University, Marseille, France
Correspondence:
[*]
Corresponding author: Eric Wersinger, SENSORION, Bâtiment INM – Hôpital St Eloi, 80 rue Augustin Fliche, BP74103 34090 Montpellier, France. E-mail: eric.wersinger@sensorion-pharma.com
Abstract: Vestibular disorders display high prevalence and can severely impact the daily life. However, pharmacological options that would efficiently relieve the vertigo symptoms without side effects are still lacking. In the present review we briefly review the common history of histamine receptor modulation and the pharmacological therapy of vestibular disorders. We also discuss the recent demonstration of Histamine H4 Receptor mRNAs expression in Scarpa's ganglion of mammal and the potential use of specific H4R antagonists as vestibulomodulators. Additional original data confirm the expression of H4R proteins in the rat vestibular primary neurons, the neuromodulatory properties of specific H4R antagonists in vitro (inhibition of vestibular neuron excitability) as well as their efficacy to decrease vestibular deficits induced in different in animal models.
